BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 34474163)

  • 1. Evaluation of Elafin as a Prognostic Biomarker in Acute Graft-versus-Host Disease.
    Zewde MG; Morales G; Gandhi I; Özbek U; Aguayo-Hiraldo P; Ayuk F; Baez J; Chanswangphuwana C; Choe H; DeFilipp Z; Etra A; Grupp S; Hexner EO; Hogan W; Javorniczky NR; Kasikis S; Kitko CL; Kowalyk S; Meedt E; Merli P; Nakamura R; Qayed M; Reshef R; Rösler W; Schechter T; Weber D; Wölfl M; Yanik G; Young R; Levine JE; Ferrara JLM; Chen YB
    Transplant Cell Ther; 2021 Dec; 27(12):988.e1-988.e7. PubMed ID: 34474163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Validated Risk Stratification That Incorporates MAGIC Biomarkers Predicts Long-Term Outcomes in Pediatric Patients with Acute GVHD.
    Qayed M; Kapoor U; Gillespie S; Westbrook A; Aguayo-Hiraldo P; Ayuk FA; Aziz M; Baez J; Choe H; DeFilipp Z; Etra A; Grupp SA; Hexner E; Holler E; Hogan WJ; Kowalyk S; Merli P; Morales G; Nakamura R; Pulsipher MA; Schechter T; Shah J; Spyrou N; Srinagesh HK; Wölfl M; Yanik G; Young R; Kitko CL; Ferrara JLM; Levine JE
    Transplant Cell Ther; 2024 Jun; 30(6):603.e1-603.e11. PubMed ID: 38548227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD.
    Major-Monfried H; Renteria AS; Pawarode A; Reddy P; Ayuk F; Holler E; Efebera YA; Hogan WJ; Wölfl M; Qayed M; Hexner EO; Wudhikarn K; Ordemann R; Young R; Shah J; Hartwell MJ; Chaudhry MS; Aziz M; Etra A; Yanik GA; Kröger N; Weber D; Chen YB; Nakamura R; Rösler W; Kitko CL; Harris AC; Pulsipher M; Reshef R; Kowalyk S; Morales G; Torres I; Özbek U; Ferrara JLM; Levine JE
    Blood; 2018 Jun; 131(25):2846-2855. PubMed ID: 29545329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amphiregulin, ST2,and REG3α Biomarker Risk Algorithms as Predictors of Non-Relapse Mortality in Patients with Acute GVHD.
    Etra AM; El Jurdi N; Katsivelos N; Kwon D; Gergoudis SC; Morales G; Spyrou N; Kowalyk S; Aguayo-Hiraldo P; Akahoshi Y; Ayuk FA; Baez J; Betts BC; Chanswangphuwana C; Chen YB; Choe HK; DeFilipp Z; Gleich S; Hexner EO; Hogan WJ; Holler E; Kitko CL; Kraus S; Al Malki MM; MacMillan ML; Pawarode A; Quagliarella F; Qayed M; Reshef R; Schechter-Finkelstein T; Vasova I; Weisdorf DJ; Wölfl M; Young R; Nakamura R; Ferrara JLM; Levine JE; Holtan SG
    Blood Adv; 2024 Apr; ():. PubMed ID: 38640195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Day 14 Endpoint for Acute GVHD Clinical Trials.
    Spyrou N; Akahoshi Y; Kowalyk S; Morales G; Beheshti R; Aguayo-Hiraldo P; Al Malki MM; Ayuk F; Bader P; Baez J; Capellini A; Choe H; DeFilipp Z; Eder M; Eng G; Etra A; Gleich S; Grupp SA; Hexner E; Hoepting M; Hogan WJ; Kasikis S; Katsivelos N; Khan A; Kitko CL; Kraus S; Kwon D; Merli P; Portelli J; Qayed M; Reshef R; Schechter T; Vasova I; Wölfl M; Wudhikarn K; Young R; Holler E; Chen YB; Nakamura R; Levine JE; Ferrara JLM
    Transplant Cell Ther; 2024 Apr; 30(4):421-432. PubMed ID: 38320730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification.
    Etra A; Gergoudis S; Morales G; Spyrou N; Shah J; Kowalyk S; Ayuk F; Baez J; Chanswangphuwana C; Chen YB; Choe H; DeFilipp Z; Gandhi I; Hexner E; Hogan WJ; Holler E; Kapoor U; Kitko CL; Kraus S; Lin JY; Al Malki M; Merli P; Pawarode A; Pulsipher MA; Qayed M; Reshef R; Rösler W; Schechter T; Van Hyfte G; Weber D; Wölfl M; Young R; Özbek U; Ferrara JLM; Levine JE
    Blood Adv; 2022 Jun; 6(12):3707-3715. PubMed ID: 35443021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of ST2 for risk of death following graft-versus-host disease in pediatric and adult age groups.
    Rowan CM; Pike F; Cooke KR; Krance R; Carpenter PA; Duncan C; Jacobsohn DA; Bollard CM; Cruz CRY; Malatpure A; Farag SS; Renbarger J; Liu H; Bakoyannis G; Hanash S; Paczesny S
    Blood; 2020 Apr; 135(17):1428-1437. PubMed ID: 31972009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretransplantation Plasma ST2 Level as a Prognostic Biomarker of 1-Year Nonrelapse Mortality in Allogeneic Hematopoietic Cell Transplantation.
    Gjærde LK; Ostrowski SR; Schierbeck F; Andersen NS; Friis LS; Kornblit B; Petersen SL; Schjødt I; Sengeløv H
    Transplant Cell Ther; 2023 Feb; 29(2):97.e1-97.e6. PubMed ID: 36375798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevation of Early Plasma Biomarkers in Patients with Clinical Risk Factors Predicts Increased Nonrelapse Mortality after Allogeneic Hematopoietic Stem Cell Transplantation.
    Hotta M; Satake A; Yoshimura H; Fujita S; Katayama Y; Ota S; Hanamoto H; Oyake T; Ito S; Okada M; Nakanishi T; Ito T; Ishii K; Nomura S
    Transplant Cell Ther; 2021 Aug; 27(8):660.e1-660.e8. PubMed ID: 33989832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease.
    Ferrara JL; Harris AC; Greenson JK; Braun TM; Holler E; Teshima T; Levine JE; Choi SW; Huber E; Landfried K; Akashi K; Vander Lugt M; Reddy P; Chin A; Zhang Q; Hanash S; Paczesny S
    Blood; 2011 Dec; 118(25):6702-8. PubMed ID: 21979939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regenerating islet-derived protein 3-α is a prognostic biomarker for gastrointestinal chronic graft-versus-host disease.
    DePriest BP; Li H; Bidgoli A; Onstad L; Couriel D; Lee SJ; Paczesny S
    Blood Adv; 2022 May; 6(10):2981-2986. PubMed ID: 35030629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic and prognostic role of elafin in skin acute graft versus host disease: a systematic review.
    Bhattarai A; Shah S; Yadav R; Dhakal G; Neupane R; Paudel S; Bhandari P; Abu Serhan H; Sah R; Sah S; Barboza JJ
    Hematology; 2024 Dec; 29(1):2293497. PubMed ID: 38112182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An early-biomarker algorithm predicts lethal graft-versus-host disease and survival.
    Hartwell MJ; Özbek U; Holler E; Renteria AS; Major-Monfried H; Reddy P; Aziz M; Hogan WJ; Ayuk F; Efebera YA; Hexner EO; Bunworasate U; Qayed M; Ordemann R; Wölfl M; Mielke S; Pawarode A; Chen YB; Devine S; Harris AC; Jagasia M; Kitko CL; Litzow MR; Kröger N; Locatelli F; Morales G; Nakamura R; Reshef R; Rösler W; Weber D; Wudhikarn K; Yanik GA; Levine JE; Ferrara JL
    JCI Insight; 2017 Feb; 2(3):e89798. PubMed ID: 28194439
    [No Abstract]   [Full Text] [Related]  

  • 14. Reg3α concentrations at day of allogeneic stem cell transplantation predict outcome and correlate with early antibiotic use.
    Weber D; Weber M; Meedt E; Ghimire S; Wolff D; Edinger M; Poeck H; Hiergeist A; Gessner A; Ayuk F; Roesler W; Wölfl M; Kraus S; Zeiser R; Bertrand H; Bader P; Ullrich E; Eder M; Gleich S; Young R; Herr W; Levine JE; Ferrara JLM; Holler E
    Blood Adv; 2023 Apr; 7(7):1326-1335. PubMed ID: 36350750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elafin as a Predictive Biomarker of Acute Skin Graft-
    Solán L; Carbonell D; Muñiz P; Dorado N; Landete E; Chicano-Lavilla M; Anguita J; Gayoso J; Kwon M; Díez-Martín JL; Martínez-Laperche C; Buño I
    Front Immunol; 2021; 12():516078. PubMed ID: 33679728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers in acute graft-
    Srinagesh HK; Levine JE; Ferrara JLM
    Ther Adv Hematol; 2019; 10():2040620719891358. PubMed ID: 31839920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations between acute GVHD-related biomarkers and endothelial cell activation after allogeneic hematopoietic stem cell transplantation.
    Nomura S; Ishii K; Fujita S; Nakaya A; Satake A; Ito T
    Transpl Immunol; 2017 Aug; 43-44():27-32. PubMed ID: 28687251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study.
    Levine JE; Braun TM; Harris AC; Holler E; Taylor A; Miller H; Magenau J; Weisdorf DJ; Ho VT; Bolaños-Meade J; Alousi AM; Ferrara JL;
    Lancet Haematol; 2015 Jan; 2(1):e21-9. PubMed ID: 26687425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in protein serum levels during stem cell transplantation.
    Metafuni E; Giammarco S; De Ritis DG; Rossi M; Corrente F; Piccirillo N; Bacigalupo AP; Sica S; Chiusolo P
    Eur J Clin Invest; 2017 Oct; 47(10):711-718. PubMed ID: 28796281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ST2 and REG3α as Predictive Biomarkers After Haploidentical Stem Cell Transplantation Using Post-transplantation High-Dose Cyclophosphamide.
    Solán L; Kwon M; Carbonell D; Dorado N; Balsalobre P; Serrano D; Chicano-Lavilla M; Anguita J; Gayoso J; Díez-Martín JL; Martínez-Laperche C; Buño I
    Front Immunol; 2019; 10():2338. PubMed ID: 31649665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.